Pulmatrix (NASDAQ:PULM) Now Covered by Analysts at StockNews.com

StockNews.com assumed coverage on shares of Pulmatrix (NASDAQ:PULMGet Rating) in a report published on Monday. The brokerage issued a hold rating on the biotechnology company’s stock.

Pulmatrix Price Performance

Pulmatrix stock opened at $3.61 on Monday. Pulmatrix has a 52 week low of $3.16 and a 52 week high of $15.60. The stock has a fifty day moving average of $3.63 and a 200-day moving average of $4.34.

Hedge Funds Weigh In On Pulmatrix

An institutional investor recently raised its position in Pulmatrix stock. Renaissance Technologies LLC lifted its holdings in shares of Pulmatrix, Inc. (NASDAQ:PULMGet Rating) by 7.3% in the second quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 121,920 shares of the biotechnology company’s stock after buying an additional 8,300 shares during the period. Renaissance Technologies LLC owned about 3.60% of Pulmatrix worth $560,000 as of its most recent filing with the SEC. 44.12% of the stock is currently owned by institutional investors and hedge funds.

About Pulmatrix

(Get Rating)

Pulmatrix, Inc, a clinical stage biotechnology company, discovers and develops inhaled therapies to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company focuses on developing products based on its inhaled small particles easily respirable and emitted (iSPERSE) technology, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications.

Recommended Stories

Receive News & Ratings for Pulmatrix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pulmatrix and related companies with MarketBeat.com's FREE daily email newsletter.